Browse studies

Find your next paid study

8 recruiting studies matching your filters

Newest first Highest paying

Phase 1

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

To find out if the combination of HC-7366 and nivolumab (with or without ipilimumab) can help to control ccRCC. The

Phase 1bHC-7366SHARK+1 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07401875

Phase 1

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

To find the best method of administering NK cells in patients with recurrent glioblastoma.

Phase 1NK CellIL13Ra+4 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07579208

Phase 1

A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.

Phase 1bOpen LabelREC-617+2 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07633756

Phase 1

A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients With Advanced Solid Tumors

The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when…

Solid Tumors (Phase 1)

Estimated

~$10 – $7,500

Adcendo ApSNCT07362888

Phase 1

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.

Phase 1SAR445877FOlfox6+4 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07500298

Phase 1

A Multi-center, Open-label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AN9025 in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

The goal of this clinical trial is to learn determine if AN9025 is safe and tolerable to treat solid cancer tumors with specific genetic mutations. It will hel…

Solid Tumors (Phase 1)RAS Mutation

Estimated

~$10 – $8,750

Adlai Nortye Biopharma Co., Ltd.NCT07252479

Phase 1

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

To find the highest tolerable dose and recommended dose of PRAME-TCR-NK cells that can be given to participants with recurrent and/or refractory melanoma. The …

Phase 1Recurrent MelanomaRefractory Melanoma

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06660420

Phase 1

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.

Clear Cell CarcinomaPhase 1Growth Factor

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07072234